Clinical Trials


DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate

This study has been completed
International Partnership for Microbicides, Inc.

Information provided by (Responsible Party)
International Partnership for Microbicides, Inc. Identifier

First received: November 14, 2012
Last updated: September 5, 2017
Last Verified: September 2017
History of Changes


This trial will investigate the potential drug-drug interaction between dapivirine vaginal Ring-004 and vaginally administered miconazole nitrate, and will evaluate the safety of co-administration of the dapivirine vaginal ring and miconazole nitrate in healthy, HIV-negative women.

Condition Intervention Phase

Drug : dapivirine
Drug : miconazole
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-label, Randomized, Three-period Crossover Trial in Healthy HIV-negative Women to Assess the Drug-drug Interaction Between Dapivirine Vaginal Ring-004 and Miconazole Nitrate

Further study details as provided by International Partnership for Microbicides, Inc.:

Primary Outcome Measures

  • Dapivirine Area under the concentration time curve (AUC) [ Time Frame: 24 hr, 14 days, and 28 days ]

Enrollment: 36
Study Start Date: December 2012
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: Dapivirine Ring + Miconazole
Dapivirine Ring + miconazole
Drug: dapivirine
Drug: miconazole
Experimental: Dapivirine Ring
Dapivirine Ring
Drug: dapivirine


Ages Eligible for Study: 18 Years to 40 Years  
Sexes Eligible for Study: Female  
Accepts Healthy Volunteers: Yes  


Inclusion Criteria:

  1. Women between 18 and ≤ 40 years of age who can give written informed consent
  2. Available for all visits and consent to follow all procedures scheduled for the trial
  3. Healthy, based on medical history, vital signs, physical examination, urinalysis (dipstick and microscopy (if indicated)), laboratory evaluations for genital infections (bacterial vaginosis, gonorrhoea, chlamydia and trichomonas), and laboratory evaluations for haematology and chemistry
  4. HIV-negative as determined by an HIV test at the time of enrolment
  5. On a stable form of contraception, defined as:
    • A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR
    • Transdermal contraceptive patch for at least 3 months prior to enrolment, OR
    • Long-acting progestins for at least 6 months prior to enrolment, OR
    • An IUD inserted (with no vaginal or gynaecological complaints associated with its use) at least 3 months prior to enrolment, OR
    • Have undergone surgical sterilisation at least 3 months prior to enrolment, AND willing to use oral contraceptives if necessary to delay menstruation during the vaginal sampling period
  6. Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal as determined by the Investigator/Physician
  7. Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any treatable STI, either clinically or by laboratory test at the time of screening, she must receive treatment at least 2 weeks prior to enrolment)
  8. Willing to refrain from the use of topical medications, vaginal products or objects, including female condoms, tampons, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying agents for 14 days prior to enrolment and for the duration of the trial.
  9. Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening
  10. Willing to refrain from participation in any other research trial for the duration of this trial
  11. Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbour contacts (confidentiality to be maintained)
  12. Willing to agree to abstain from all the following for a total of 2 days (48 hours) prior to each trial visit:
    • Penile-vaginal intercourse
    • Oral contact with her genitalia
  13. Hepatitis B and C negative at the time of enrolment.

  • Exclusion Criteria:
  • Currently pregnant or had their last pregnancy outcome within 3 months prior to screening
  • Currently breast-feeding
  • Currently or within two months of participation in any other clinical research trial involving investigational or marketed products prior to screening
  • Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually transmitted infections, or other gynaecological conditions such as vaginal itching, pain, or discharge, within 2 weeks prior to enrolment
  • Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies
  • History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence
  • Current vulvar or vaginal symptoms/abnormalities that could influence the trial results
  • Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
  • Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection
  • Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies
  • Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrolment
  • Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone
  • Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm, cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition
  • Have undergone a hysterectomy
  • Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.

    contacts and locations

    Contacts and Locations

    Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

    Please refer to this study by its identifier: NCT01731574


    SGS Life Sciences
    Lange Beeldekensstraat 267, Antwerpen, Belgium, B-2060

    Sponsors and Collaborators

    International Partnership for Microbicides, Inc.
    More Information

    More Information

    Responsible Party: International Partnership for Microbicides, Inc. Identifier: NCT01731574   History of Changes  
    Other Study ID Numbers: IPM 028  
    Study First Received: November 14, 2012  
    Last Updated: September 5, 2017  

    Studies a U.S. FDA-regulated Drug Product: Yes  
    Studies a U.S. FDA-regulated Device Product: No  

    Additional relevant MeSH terms:
    Miconazole processed this data on June 02, 2020
    This information is provided by